Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $71.2 million.

  • C4 Therapeutics' Shares Outstanding (Weighted Average) rose 2.64% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.2 million, marking a year-over-year increase of 2.64%. This contributed to the annual value of $70.6 million for FY2024, which is 43.24% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Shares Outstanding (Weighted Average) is $71.2 million, which was up 0.23% from $71.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $71.2 million in Q3 2025 and a low of $43.1 million during Q1 2021.
  • In the last 3 years, C4 Therapeutics' Shares Outstanding (Weighted Average) had a median value of $68.8 million in 2024 and averaged $62.5 million.
  • Data for C4 Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 43.24% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Shares Outstanding (Weighted Average) stood at $48.6 million in 2021, then grew by 0.68% to $49.0 million in 2022, then climbed by 0.66% to $49.3 million in 2023, then skyrocketed by 43.24% to $70.6 million in 2024, then increased by 2.64% to $71.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $71.2 million for Q3 2025, versus $71.0 million for Q2 2025 and $71.0 million for Q1 2025.